Minnesota HF4357 prohibits health plans from using step therapy protocols for treating neurological conditions.

Minnesota HF4357 prohibits health plans from requiring enrollees with neurological conditions to follow step therapy protocols for FDA-approved drugs. This means that if a drug is approved by the FDA and listed on the health plan's formulary, it cannot be restricted by requiring patients to try other treatments first. The bill applies to health plans offered, issued, or renewed on or after January 1, 2027.

Minnesota HF4357 prohibits health plans from using step therapy protocols for treating neurological conditions.

Minnesota HF4357 prohibits health plans from requiring enrollees with neurological conditions to follow step therapy protocols for FDA-approved drugs. This means that if a drug is approved by the FDA and listed on the health plan's formulary, it cannot be restricted by requiring patients to try other treatments first. The bill applies to health plans offered, issued, or renewed on or after January 1, 2027.